{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T18:28:26Z","timestamp":1794508106331,"version":"4.9.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008333","name":"University of Alabama at Birmingham","doi-asserted-by":"publisher","award":["Intramural award"],"award-info":[{"award-number":["Intramural award"]}],"id":[{"id":"10.13039\/100008333","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>While doxycycline postexposure prophylaxis (doxyPEP) can prevent bacterial sexually transmitted infections (STIs), concern surrounds the volume of antibiotic use needed to realize this benefit. We estimated incidence rates of gonorrhea, chlamydia, and syphilis diagnoses and related antibiotic prescribing among US males and transgender individuals using Merative MarketScan\u00ae Research Databases during 2017-2019. Follow-up encompassed 38,543 person-years among recipients of HIV pre-exposure prophylaxis (PrEP), 29,228 person-years among people living with HIV (PLWH), and 19,918 person-years among people with prior-year STI diagnoses. Incidence rates of STI diagnoses among PLWH and PrEP recipients with \u22651 prior-year STI diagnosis totaled 33.3-35.5 per 100 person-years. Direct effects of doxyPEP could prevent 7.4-9.6 gonorrhea diagnoses, 7.3-8.1 chlamydia diagnoses, and 3.1-5.9 syphilis diagnoses per 100 person-years of use. However, expected increases in tetracycline consumption resulting from doxyPEP implementation totaled 271.9-312.9 additional 7-day doxycycline treatment courses per 100 person-years of use. These increases corresponded to 37.0-38.7, 36.5-37.0, and 46.1-100.2 additional 7-day doxycycline treatment courses for each prevented gonorrhea, chlamydia, and syphilis diagnosis, respectively. Increases in doxycycline use exceeded anticipated reductions in STI-related prescribing of cephalosporins, macrolides, and penicillins by 16\u201369-fold margins. Anticipated changes in antibiotic use as well as STI incidence should inform priority-setting for doxyPEP.<\/jats:p>","DOI":"10.1038\/s41467-025-64261-w","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:17:50Z","timestamp":1760606270000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Bacterial sexually transmitted infections and related antibiotic use among individuals eligible for doxycycline post-exposure prophylaxis in the United States"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9038-894X","authenticated-orcid":false,"given":"Anna M.","family":"Parker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer J.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ligong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra I.","family":"McCoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8505-8839","authenticated-orcid":false,"given":"Joseph A.","family":"Lewnard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8277-2431","authenticated-orcid":false,"given":"Katia J.","family":"Bruxvoort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"64261_CR1","unstructured":"US Centers for Disease Control and Prevention. Sexually Transmitted Infections Surveillance, 2023. https:\/\/www.cdc.gov\/sti-statistics\/annual\/index.html (2025)."},{"key":"64261_CR2","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/cid\/ciy182","volume":"67","author":"MW Traeger","year":"2018","unstructured":"Traeger, M. W. et al. Effects of pre-exposure prophylaxis for the prevention of human immunodeficiency virus infection on sexual risk behavior in men who have sex with men: a systematic review and meta-analysis. Clin. Infect. Dis. 67, 676\u2013686 (2018).","journal-title":"Clin. Infect. Dis."},{"key":"64261_CR3","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1007\/s10461-018-2252-9","volume":"23","author":"MA Monta\u00f1o","year":"2019","unstructured":"Monta\u00f1o, M. A. et al. Changes in sexual behavior and STI diagnoses among MSM initiating PrEP in a clinic setting. AIDS Behav. 23, 548\u2013555 (2019).","journal-title":"AIDS Behav."},{"key":"64261_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7302a1","volume":"73","author":"LH Bachmann","year":"2024","unstructured":"Bachmann, L. H. CDC clinical guidelines on the use of doxycycline postexposure prophylaxis for bacterial sexually transmitted infection prevention, United States, 2024. MMWR Recomm. Rep. 73, 1\u20138 (2024).","journal-title":"MMWR Recomm. Rep."},{"key":"64261_CR5","first-page":"553","volume":"73","author":"H Peyriere","year":"2018","unstructured":"Peyriere, H., Makinson, A., Marchandin, H. & Reynes, J. Doxycycline in the management of sexually transmitted infections. J. Antimicrob. Chemother. 73, 553\u2013563 (2018).","journal-title":"J. Antimicrob. Chemother."},{"key":"64261_CR6","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/S1473-3099(17)30725-9","volume":"18","author":"JM Molina","year":"2018","unstructured":"Molina, J. M. et al. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect. Dis. 18, 308\u2013317 (2018).","journal-title":"Lancet Infect. Dis."},{"key":"64261_CR7","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa2211934","volume":"388","author":"AF Luetkemeyer","year":"2023","unstructured":"Luetkemeyer, A. F. et al. Postexposure doxycycline to prevent bacterial sexually transmitted infections. N. Engl. J. Med. 388, 1296\u20131306 (2023).","journal-title":"N. Engl. J. Med."},{"key":"64261_CR8","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/OLQ.0000000000000216","volume":"42","author":"RK Bolan","year":"2015","unstructured":"Bolan, R. K. et al. Doxycycline prophylaxis to reduce incident syphilis among HIV-infected men who have sex with men who continue to engage in high-risk sex: a randomized, controlled pilot study. Sex. Transm. Dis. 42, 98 (2015).","journal-title":"Sex. Transm. Dis."},{"key":"64261_CR9","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1093\/jac\/dkad129","volume":"78","author":"FYS Kong","year":"2023","unstructured":"Kong, F. Y. S., Kenyon, C. & Unemo, M. Important considerations regarding the widespread use of doxycycline chemoprophylaxis against sexually transmitted infections. J. Antimicrob. Chemother. 78, 1561\u20131568 (2023).","journal-title":"J. Antimicrob. Chemother."},{"key":"64261_CR10","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.15585\/mmwr.mm6950a6","volume":"69","author":"SS Cyr","year":"2020","unstructured":"Cyr, S. S. Update to CDC\u2019s treatment guidelines for gonococcal infection, 2020. Morb. Mortal. Wkly. Rep. 69, 1911\u20131916 (2020).","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"64261_CR11","doi-asserted-by":"publisher","unstructured":"Reichert, E. & Grad, Y. H. Resistance and prevalence implications of doxycycline post-exposure prophylaxis for gonorrhea prevention in men who have sex with men: a modeling study. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2023.04.24.23289033 (2024).","DOI":"10.1101\/2023.04.24.23289033"},{"key":"64261_CR12","doi-asserted-by":"crossref","unstructured":"Mittelstaedt, R., Kanjilal, S., Helekal, D., Robbins, G. K. & Grad, Y. H. Staphylococcus aureus tetracycline resistance and co-resistance in a doxyPEP-eligible population. J. Infect. Dis. 231, e708\u2013e712 (2024).","DOI":"10.1093\/infdis\/jiae634"},{"key":"64261_CR13","doi-asserted-by":"publisher","first-page":"dlac009","DOI":"10.1093\/jacamr\/dlac009","volume":"4","author":"R Truong","year":"2022","unstructured":"Truong, R., Tang, V., Grennan, T. & Tan, D. H. S. A systematic review of the impacts of oral tetracycline class antibiotics on antimicrobial resistance in normal human flora. JAC Antimicrob. Resist. 4, dlac009 (2022).","journal-title":"JAC Antimicrob. Resist."},{"key":"64261_CR14","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41591-024-03274-2","volume":"31","author":"VT Chu","year":"2024","unstructured":"Chu, V. T. et al. Impact of doxycycline post-exposure prophylaxis for sexually transmitted infections on the gut microbiome and antimicrobial resistome. Nat. Med. 31, 207\u2013217 (2024).","journal-title":"Nat. Med."},{"key":"64261_CR15","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1016\/S2666-5247(23)00314-2","volume":"5","author":"KIO Roster","year":"2024","unstructured":"Roster, K. I. O. & Grad, Y. H. Estimating changes in antibiotic consumption in the USA with the introduction of doxycycline post-exposure prophylaxis. Lancet Microbe 5, e9 (2024).","journal-title":"Lancet Microbe"},{"key":"64261_CR16","doi-asserted-by":"publisher","unstructured":"Traeger, M. W. et al. Potential impact of doxycycline post-exposure prophylaxis prescribing strategies on incidence of bacterial sexually transmitted infections. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciad488 (2023).","DOI":"10.1093\/cid\/ciad488"},{"key":"64261_CR17","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1136\/sextrans-2024-056152","volume":"100","author":"PA Chan","year":"2024","unstructured":"Chan, P. A. et al. Early adopters of doxycycline as post-exposure prophylaxis to prevent bacterial sexually transmitted infections in a real-world clinical setting. Sex. Transm. Infect. 100, 339\u2013342 (2024).","journal-title":"Sex. Transm. Infect."},{"key":"64261_CR18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1136\/sextrans-2024-056291","volume":"101","author":"A Ogunbajo","year":"2025","unstructured":"Ogunbajo, A. et al. Predictors of receiving a doxycycline postexposure prophylaxis (Doxy-PEP) prescription for the prevention of bacterial sexually transmitted infections (STIs) in a community-based clinic: a case\u2013control study. Sex. Transm. Infect. 101, 68\u201369 (2025).","journal-title":"Sex. Transm. Infect."},{"key":"64261_CR19","doi-asserted-by":"publisher","unstructured":"Raccagni, A. R. et al. DoxyPEP: real-life effectiveness in a cohort of men who have sex with men in Milan, Italy. Lancet Infect. Dis. https:\/\/doi.org\/10.1016\/S1473-3099(24)00726-6 (2024).","DOI":"10.1016\/S1473-3099(24)00726-6"},{"key":"64261_CR20","doi-asserted-by":"publisher","unstructured":"Sergio, V. B., Ruben, M. & Luis, V. A practice already in use: a snapshot survey on the use of doxycycline as a preventive strategy (Doxy-PEP and Doxy-PrEP) in the GBMSM population in Spain. Infection. https:\/\/doi.org\/10.1007\/s15010-024-02320-y (2024).","DOI":"10.1007\/s15010-024-02320-y"},{"key":"64261_CR21","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.15585\/mmwr.mm7047a3","volume":"70","author":"AR Baugher","year":"2021","unstructured":"Baugher, A. R. Racial, ethnic, and gender disparities in awareness of preexposure prophylaxis among HIV-negative heterosexually active adults at increased risk for HIV infection\u201423 urban areas, United States, 2019. Morb. Mortal. Wkly. Rep. 70, 1635\u20131639 (2021).","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"64261_CR22","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1097\/QAD.0000000000002111","volume":"33","author":"N Crepaz","year":"2019","unstructured":"Crepaz, N., Hess, K. L., Purcell, D. W. & Hall, H. I. Estimating national rates of HIV infection among MSM, persons who inject drugs, and heterosexuals in the United States. AIDS 33, 701 (2019).","journal-title":"AIDS"},{"key":"64261_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2024.107186","author":"I Szondy","year":"2024","unstructured":"Szondy, I. et al. Doxycycline prophylaxis for the prevention of sexually transmitted infections: a systematic review and meta-analysis of randomised controlled trials. Int. J. Infect. Dis. https:\/\/doi.org\/10.1016\/j.ijid.2024.107186 (2024).","journal-title":"Int. J. Infect. Dis."},{"key":"64261_CR24","doi-asserted-by":"publisher","first-page":"100871","DOI":"10.1016\/j.lanepe.2024.100871","volume":"38","author":"M Unemo","year":"2024","unstructured":"Unemo, M. et al. High tetracycline resistance percentages in Neisseria gonorrhoeae in Europe: is doxycycline post-exposure prophylaxis unlikely to reduce the incident gonorrhea cases? Lancet Reg. Health Eur. 38, 100871 (2024).","journal-title":"Lancet Reg. Health Eur."},{"key":"64261_CR25","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1093\/cid\/ciaf089","volume":"80","author":"OO Soge","year":"2025","unstructured":"Soge, O. O. et al. Potential impact of doxycycline post-exposure prophylaxis on tetracycline resistance in Neisseria gonorrhoeae and colonization with tetracycline-resistant Staphylococcus aureus and group A Streptococcus. Clin. Infect. Dis. 80, 1181\u20131196 (2025).","journal-title":"Clin. Infect. Dis."},{"key":"64261_CR26","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1093\/jac\/dkaf066","volume":"80","author":"D Schr\u00f6der","year":"2025","unstructured":"Schr\u00f6der, D. et al. Exceedingly high levels of tetracycline resistance in Neisseria gonorrhoeae in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021\u20132024\u2014doxycycline post-exposure prophylaxis will unlikely impact gonorrhoea burdens. J. Antimicrob. Chemother. 80, 1291\u20131295 (2025).","journal-title":"J. Antimicrob. Chemother."},{"key":"64261_CR27","doi-asserted-by":"publisher","first-page":"e316","DOI":"10.1016\/S1473-3099(25)00234-8","volume":"25","author":"T Vanbaelen","year":"2025","unstructured":"Vanbaelen, T., Manoharan-Basil, S. S. & Kenyon, C. Doxy-PEP could select for ceftriaxone resistance in Neisseria gonorrhoeae. Lancet Infect. Dis. 25, e316 (2025).","journal-title":"Lancet Infect. Dis."},{"key":"64261_CR28","doi-asserted-by":"publisher","unstructured":"Reichert, E. & Grad, Y. H. Effects of doxycycline post-exposure prophylaxis for prevention of sexually transmitted infections on gonorrhoea prevalence and antimicrobial resistance among men who have sex with men in the USA: a modelling study. Lancet Microbe. https:\/\/doi.org\/10.1016\/S2666-5247(24)00168-X (2024).","DOI":"10.1016\/S2666-5247(24)00168-X"},{"key":"64261_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07171-2","volume":"22","author":"NHTM Dukers-Muijrers","year":"2022","unstructured":"Dukers-Muijrers, N. H. T. M. et al. Controversies and evidence on Chlamydia testing and treatment in asymptomatic women and men who have sex with men: a narrative review. BMC Infect. Dis. 22, 255 (2022).","journal-title":"BMC Infect. Dis."},{"key":"64261_CR30","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1136\/sextrans-2020-054500","volume":"96","author":"S Mensforth","year":"2020","unstructured":"Mensforth, S., Ayinde, O. C. & Ross, J. Spontaneous clearance of genital and extragenital Neisseria gonorrhoeae: data from GToG. Sex. Transm. Infect. 96, 556\u2013561 (2020).","journal-title":"Sex. Transm. Infect."},{"key":"64261_CR31","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/OLQ.0b013e3181d73639","volume":"37","author":"SK Apewokin","year":"2010","unstructured":"Apewokin, S. K., Geisler, W. M. & Bachmann, L. H. Spontaneous resolution of extragenital chlamydial and gonococcal infections prior to therapy. Sex. Transm. Dis. 37, 343 (2010).","journal-title":"Sex. Transm. Dis."},{"key":"64261_CR32","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1017\/ice.2017.94","volume":"38","author":"JS Gerber","year":"2017","unstructured":"Gerber, J. S. et al. Development and application of an antibiotic spectrum index for benchmarking antibiotic selection patterns across hospitals. Infect. Control Hosp. Epidemiol. 38, 993\u2013997 (2017).","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"64261_CR33","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1093\/cid\/ciab1034","volume":"75","author":"S Kakiuchi","year":"2022","unstructured":"Kakiuchi, S. et al. Days of antibiotic spectrum coverage: a novel metric for inpatient antibiotic consumption. Clin. Infect. Dis. 75, 567\u2013576 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"64261_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-60041-6","volume":"14","author":"M de Lorenzi-Tognon","year":"2024","unstructured":"de Lorenzi-Tognon, M. & Schrenzel, J. Simplified Spectrum Score (S3) app for pathogen-agnostic antimicrobial drug spectrum ranking to assess for antimicrobial de-escalation events. Sci. Rep. 14, 9776 (2024).","journal-title":"Sci. Rep."},{"key":"64261_CR35","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s40506-019-00188-3","volume":"11","author":"ME Yarrington","year":"2019","unstructured":"Yarrington, M. E. & Moehring, R. W. Basic, advanced, and novel metrics to guide antibiotic use assessments. Curr. Treat. Options Infect. Dis. 11, 145\u2013160 (2019).","journal-title":"Curr. Treat. Options Infect. Dis."},{"key":"64261_CR36","doi-asserted-by":"publisher","first-page":"e0178737","DOI":"10.1371\/journal.pone.0178737","volume":"12","author":"RR Patel","year":"2017","unstructured":"Patel, R. R. et al. Impact of insurance coverage on utilization of pre-exposure prophylaxis for HIV prevention. PLoS ONE 12, e0178737 (2017).","journal-title":"PLoS ONE"},{"key":"64261_CR37","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1097\/QAI.0000000000001236","volume":"74","author":"S Doblecki-Lewis","year":"2017","unstructured":"Doblecki-Lewis, S. et al. Healthcare access and PrEP continuation in San Francisco and Miami after the US PrEP Demo Project. J. Acquir. Immune Defic. Syndr. 74, 531 (2017).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"64261_CR38","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1089\/apc.2017.0171","volume":"31","author":"SJ Marks","year":"2017","unstructured":"Marks, S. J. et al. Potential healthcare insurance and provider barriers to pre-exposure prophylaxis utilization among young men who have sex with men. AIDS Patient Care STDs 31, 470\u2013478 (2017).","journal-title":"AIDS Patient Care STDs"},{"key":"64261_CR39","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1097\/OLQ.0b013e31829529cf","volume":"40","author":"G Harling","year":"2013","unstructured":"Harling, G., Subramanian, S. V., B\u00e4rnighausen, T. & Kawachi, I. Socioeconomic disparities in sexually transmitted infections among young adults in the United States: examining the interaction between income and race\/ethnicity. Sex. Transm. Dis. 40, 575 (2013).","journal-title":"Sex. Transm. Dis."},{"key":"64261_CR40","doi-asserted-by":"publisher","DOI":"10.1071\/SH23176","author":"KD Samuel","year":"2024","unstructured":"Samuel, K. D., Ellis, M. S. & Buttram, M. E. The impact of socio-environmental factors on doxycycline post-exposure prophylaxis awareness in the US: a cross-sectional study. Sex. Health. https:\/\/doi.org\/10.1071\/SH23176 (2024).","journal-title":"Sex. Health."},{"key":"64261_CR41","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/S1473-3099(24)00408-0","volume":"24","author":"KIO Roster","year":"2024","unstructured":"Roster, K. I. O., Mittelstaedt, R., Reyes, J., Aatresh, A. V. & Grad, Y. H. Modelling molecular and culture-based surveillance of tetracycline resistance in Neisseria gonorrhoeae. Lancet Infect. Dis. 24, 806\u2013808 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"64261_CR42","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1177\/0033354920904085","volume":"135","author":"NW Furukawa","year":"2020","unstructured":"Furukawa, N. W. et al. Evaluation of algorithms used for PrEP surveillance using a reference population from New York City, July 2016\u2013June 2018. Public Health Rep. 135, 202\u2013210 (2020).","journal-title":"Public Health Rep."},{"key":"64261_CR43","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/OLQ.0000000000001763","volume":"50","author":"ED Pollock","year":"2023","unstructured":"Pollock, E. D., Clay, P. A., Kreisel, K. M. & Spicknall, I. H. Estimated incidence and prevalence of gonorrhea in the United States, 2006\u20132019. Sex. Transm. Dis. 50, 188 (2023).","journal-title":"Sex. Transm. Dis."},{"key":"64261_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.ss6507a1","volume":"65","author":"RD Kirkcaldy","year":"2016","unstructured":"Kirkcaldy, R. D. Neisseria gonorrhoeae antimicrobial susceptibility surveillance\u2014the Gonococcal Isolate Surveillance Project, 27 sites, United States, 2014. MMWR Surveill. Summ. 65, 1\u201319 (2016).","journal-title":"MMWR Surveill. Summ."},{"key":"64261_CR45","doi-asserted-by":"publisher","first-page":"100386","DOI":"10.1016\/j.epidem.2020.100386","volume":"30","author":"KM Weiss","year":"2020","unstructured":"Weiss, K. M. et al. Egocentric sexual networks of men who have sex with men in the United States: results from the ARTnet study. Epidemics 30, 100386 (2020).","journal-title":"Epidemics"},{"key":"64261_CR46","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1097\/QAD.0000000000003343","volume":"36","author":"LM Mann","year":"2022","unstructured":"Mann, L. M. et al. Correlations between community-level HIV preexposure prophylaxis coverage and individual-level sexual behaviors among United States MSM. AIDS 36, 2015\u20132023 (2022).","journal-title":"AIDS"},{"key":"64261_CR47","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/OLQ.0000000000000410","volume":"43","author":"C Grov","year":"2016","unstructured":"Grov, C., Cain, D., Rendina, H. J., Ventuneac, A. & Parsons, J. T. Characteristics associated with urethral and rectal gonorrhea and chlamydia diagnoses in a US national sample of gay and bisexual men: results from the One Thousand Strong panel. Sex. Transm. Dis. 43, 165 (2016).","journal-title":"Sex. Transm. Dis."},{"key":"64261_CR48","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1136\/sti.2006.021915","volume":"83","author":"F Jin","year":"2007","unstructured":"Jin, F. et al. Incidence and risk factors for urethral and anal gonorrhoea and chlamydia in a cohort of HIV-negative homosexual men: the Health in Men Study. Sex. Transm. Infect. 83, 113\u2013119 (2007).","journal-title":"Sex. Transm. Infect."},{"key":"64261_CR49","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1177\/09564624231173728","volume":"34","author":"P Janulis","year":"2023","unstructured":"Janulis, P. et al. Partnership types and coital frequency as predictors of gonorrhea and chlamydia among young MSM and young transgender women. Int. J. STD AIDS 34, 694\u2013701 (2023).","journal-title":"Int. J. STD AIDS"},{"key":"64261_CR50","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1136\/bmj.310.6977.452","volume":"310","author":"RJ Cook","year":"1995","unstructured":"Cook, R. J. & Sackett, D. L. The number needed to treat: a clinically useful measure of treatment effect. BMJ 310, 452\u2013454 (1995).","journal-title":"BMJ"},{"key":"64261_CR51","doi-asserted-by":"publisher","unstructured":"Parker, A. M. Bacterial sexually transmitted infections and related antibiotic use among individuals eligible for doxycycline post-exposure prophylaxis in the United States, joelewnard\/doxyPEP, Release v1.0.0. Zenodo https:\/\/doi.org\/10.5281\/zenodo.16704920 (2025).","DOI":"10.5281\/zenodo.16704920"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64261-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64261-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64261-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T10:04:53Z","timestamp":1760609093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64261-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["64261"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-64261-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]},"assertion":[{"value":"29 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9206"}}